Это первое всеобъемлющее и самое актуальное обозрение данной темы. Эта справочная книга и руководство обобщает текущие знания о TAAs (антигенах, ассоциированных с опухолями), их подклассах и указывает области их применения в медицине. Кроме того, в ней подчеркивается важность идентификации мишеней, необходимость точного и тщательного анализа функций TAAs, а также валидации их использования в клинических условиях. В заключение приводится обзор одобренных в настоящее время терапевтических антител. Эта книга незаменима для биологов и онкологов, работающих в науке, клиниках и промышленности.
The first comprehensive and state-of-the-art overview of tumor-associated antigens, to your service and aid as a ready reference guide, explores and inspects current facets of TAA understanding, their established classifications, as well as identifies their applicable applications in medical treatment. Above all, it highlights the unique strategies utilized for finding potential proteins to use as anti-tumour targets, the critical importance of obtaining an explicit and exhaustive grasp regarding the functions of TAA, as well the pivotal significance of evaluating these in the modern clinical milieu. Eventually executed with an overview on the wide array of novel treatment antibodies which are now under approval, the outcome is surely going to be a essential possession for bioscientists and medical oncologists across the scientific, clinical, and industrial sectors.
Электронная Книга «Tumor-Associated Antigens» написана автором Olivier Gires в году.
Минимальный возраст читателя: 0
Язык: Английский
ISBN: 9783527625987
Описание книги от Olivier Gires
The first comprehensive and most recent overview of the topic, this ready reference and handbook reviews current knowledge of TAAs, their subclasses, and pinpoints their application areas in medicine. In addition, it emphasizes target identification procedures, the need for an accurate and thorough analysis of the function of TAAs, and the validation of those in clinical settings. The whole is rounded off with an overview of currently approved therapeutic antibodies. The result is a must-have for biologists and oncologists in science, clinics and industry.
